Loading
ABC-12 collects mouth and bowel bacteria samples from UK patients having standard chemotherapy with durvalumab for bile duct or gallbladder cancer, to see whether the microbiome predicts who responds.
ABC-12 (ISRCTN11210442) is a UK study, led from The Christie with AstraZeneca support, in patients with biliary tract adenocarcinoma, including cholangiocarcinoma and gallbladder carcinoma, receiving durvalumab with cisplatin and gemcitabine as their standard of care. The primary outcome is baseline alpha diversity (number of species) in microbiome samples from responders (partial or complete response by RECIST 1.1) and non-responders at 18 weeks. Seventy patients are targeted at ten NHS trusts (The Christie, Imperial, Cambridge, Royal Free, Oxford, Birmingham, Clatterbridge, Nottingham, Velindre and University College London Hospitals) with an end date of September 2026. It is a companion study to the TOPAZ-1 standard rather than a treatment trial.
Criteria as posted are in the stored snapshot. Read 2026-10-07.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Biliary tract cancer (cholangiocarcinoma).
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Biliary tract cancer (cholangiocarcinoma).
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Biliary tract cancer (cholangiocarcinoma).
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Biliary tract cancer (cholangiocarcinoma).
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma), Gallbladder cancer.
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Durvalumab, Biliary tract cancer (cholangiocarcinoma).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/